Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases

Blood

Volumn 101, Issue 4, 2003, Pages 1620-1629

  Niederwieser, Dietger ^a   Maris, Michael ^b   Shizuru, Judith A ^b   Petersdorf, Effie ^b   Hegenbart, Ute ^b   Sandmaier, Brenda M ^b   Maloney, David G ^b   Storer, Barry ^b   Lange, Thoralf ^b   Chauncey, Thomas ^b   Deininger, Michael ^b   Pönisch, Wolfram ^b   Anasetti, Claudio ^b   Woolfrey, Ann ^b   Little, Marie Terese ^b   Blume, Karl G ^b   McSweeney, Peter A ^b   Storb, Rainer F ^b  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALOPECIA; ARTICLE; BLOOD DISEASE; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; GRANULOCYTE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; NAUSEA; NEPHROTOXICITY; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHASE 1 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; REMISSION; SURVIVAL TIME; T LYMPHOCYTE; TIME SERIES ANALYSIS; TREATMENT OUTCOME; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

EID: 0037441604     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-05-1340     Document Type: Article

References (34)

1. Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med. 1998;338:962-968.
2. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by The National Marrow Donor Program. N Engl J Med. 1993;328:593-602.
3. McGlave PB, Shu XO, Wen W, et al. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood. 2000;95:2219-2225.
4. Molina AJ, Storb RF. Hematopoietic stem cell transplantation in older adults. In: Rowe JM, Lazarus HM, Carella AM, eds. Handbook of Bone Marrow Transplantation. 1st ed. London, United Kingdom: Martin Dunitz; 2000:111-137.
5. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
6. Khouri IF, Keating M, Körbling M, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol. 1998;16:2817-2824.
7. Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood. 1999;94:3234-3241.
8. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versuslymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755-1759.
9. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
10. Nagler A, Aker M, Or R, et al. Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol. 2001;29:362-370.
11. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versustumor effects. Blood. 2001;97:3390-3400.
12. Chakraverty R, Peggs K, Chopra R, et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood. 2002;99:1071-1078.
13. Storb R, Yu C, Wagner JL, Deeg HJ, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood. 1997;89:3048-3054.
14. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood. 1998;92:3515-3520.
15. Petersdorf EW, Gooley T, Malkki M, et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation. Br J Haematol. 2001;112:988-994.
16. Meyers JD, Petersen FB, Counts GW, et al. Bacterial, fungal and protozoan infection after marrow transplantation. In: Baum SJ, Santos GW, Takaku F, eds. Recent Advances and Future Directions in Bone Marrow Transplantation: Experimental Hematology Today - 1987. New York, NY: Springer Verlag; 1988:171-176.
17. Slavin MA, Osborne B, Adama R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double-blind study. J Infect Dis. 1995;171:1545-1552.
18. Boeckh M, Bowden RA, Goodrich JM, Pettinger M, Meyers JD. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood. 1992;80:1358-1364.
19. Bryant E, Martin PJ. Documentation of engraftment and characterization of chimerism following hematopoietic cell transplantation. In: Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic Cell Transplantation. 2nd ed. Boston, MA: Blackwell Science; 1999:197-206.
20. Przepiorka D, Weisdorf D, Martin P, et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15:825-828.
21. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol. 1991;28:250-259.
22. Radich J, Ladne P, Gooley T. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT. Biol Blood Marrow Transplant. 1995;1:24-31.
23. Andersen PK, Borgan O, Gill RD, Keiding N. Statistical Models Based on Counting Processes. New York, NY: Springer-Verlag; 1993.
24. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versushost disease: initial treatment. Blood. 1990;76:1464-1472.
25. Blecker D, Bansal M, Zimmerman RL, et al. Dieulafoy's lesion of the small bowel causing massive gastrointestinal bleeding: two case reports and literature review (review). Am J Gastroenterol. 2001;96:902-905.
26. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose. Blood. 1997;89:4226-4235.
27. Radich JP, Gooley T, Sanders JE, Anasetti C, Chauncey T, Appelbaum FR. Second allogeneic transplantation after failure of first autologous transplantation. Biol Blood Marrow Transplant. 2000;6:272-279.
28. Weissinger F, Sandmaier BM, Maloney DG, Bensinger WI, Gooley T, Storb R. Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings. Blood. 2001;98:3584-3588.
29. Comelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graftversus-leukemia effect and risk factors determining outcome. Blood. 2001;97:1572-1577.
30. Ferrara JL. Pathogenesis of acute graft-versus-host disease: cytokines and cellular effectors (review). J Hematother Stem Cell Res. 2000;9:299-306.
31. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-2100.
32. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy (review). Immunol Rev. 1997;157:125-140.
33. Warren EH, Gavin MA, Simpson E, et al. The human UTY gene encodes a novel HLA-B8-restricted H-Y antigen. J Immunol. 2000;164:2807-2814.
34. Mutis T, Verdijk R, Schrama E, Esendam B, Brand A, Goulmy E. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999;93:2336-2341.